I will start my new chemotherapy tomorrow - ARQ 197 (tivantinib) as part of the Clinical Trial
I'll take 360 mg of the drug twice a day with my breakfast and dinner. The only "caution" is no grapefruit or grapefruit juice. It's amazing how many drugs are incompatible with that healthy fruit!
Being on this trial will require regular trips to Dana Farber - every other week after the first few weeks. They are going to get tired of seeing me!!! And I get to stay on the trial drug for as long as it's effective. So we're hoping for a nice long run with very gentle side effects. Based on the documentation and what I've read, fatigue seems to be the biggest complaint. Less than 20% of participants have problems with low blood counts and a list of other things, nothing too daunting.
I feel like a pioneer! There are just 40 participants in this trial and I get to be one of them. I think they have expanded the size of the trial because initially, it was 26 and Dana Farber had just 2 slots. I think the clinical trial world is ever-changing.
I am very optimistic that this drug will be effective for me and hopefully, a future treatment for all triple negative breast cancer sisters.
Keep your fingers crossed!